<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018328</url>
  </required_header>
  <id_info>
    <org_study_id>rmc137511</org_study_id>
    <nct_id>NCT02018328</nct_id>
  </id_info>
  <brief_title>The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection</brief_title>
  <acronym>CurHP</acronym>
  <official_title>The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gingold Belfer Rachel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Aims&#xD;
&#xD;
        -  H.pylori is a common human pathogen by which almost 50% of the world population is&#xD;
           infected. According to the accepted guidelines, once H.pylori infection has been&#xD;
           diagnosed,first line therapy with three drugs should be given. The triple treatment&#xD;
           includes proton-pump-inhibitor-clarithromycin-amoxicillin but its eradication rate is&#xD;
           only 70-80%.&#xD;
&#xD;
        -  Curcumin has many beneficial merits and it was also been demonstrated to be efficient in&#xD;
           inhibition of H.pylori infection, in vitro.Therefore we aim to investigate whether&#xD;
           addition of Curcumin to the standard triple therapy will increase the eradication rate&#xD;
           of H.pylori infection.&#xD;
&#xD;
      Methods&#xD;
&#xD;
        -  150 consecutive patients that will undergo esophagogastroscopy in our Gastroenterology&#xD;
           department and will be positive for H.pylori according to urease test and then by&#xD;
           gastric biopsy, will be included. The patients will be randomized to two different&#xD;
           treatments, according to binomial distribution. 75 patients will be treated with the&#xD;
           standard triple therapy for 10 days and the other 75, will be treated for 10 days, with&#xD;
           triple therapy combined with Curcumin that will be given three times a day.&#xD;
&#xD;
        -  During the treatment the patients will complete an adverse effect's questionnaires. 6&#xD;
           weeks after the completion of the treatment the patients will undergo urea breath test&#xD;
           to confirm eradication. Patients will be asked to avoid antibiotics, bismuth compounds&#xD;
           or proton-pump-inhibitor until the second urea-breath-test.&#xD;
&#xD;
        -  We will compare the eradication rate and the adverse effects between the two groups by&#xD;
           using SPSS&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urea breath test</measure>
    <time_frame>6 weeks after the completion of the treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Positivity for Helicobacter Pylori</condition>
  <arm_group>
    <arm_group_label>Triple therapy, helicobacter pylori</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>triple therapy+curcumin helicobacter pylori</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin will be added to the regular triple therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <arm_group_label>triple therapy+curcumin helicobacter pylori</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positivity for Helicobacter pylori by urease test and gastric biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior treatment for H. pylori&#xD;
&#xD;
          -  allergy to penicillin&#xD;
&#xD;
          -  gastric outlet obstruction&#xD;
&#xD;
          -  pregnancy or breast feeding&#xD;
&#xD;
          -  inability to understand the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rachel Gingold belfer, MD</last_name>
    <email>RahelGB@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <phone>974-54-2405895</phone>
      <email>RahelGB@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Rachel Gingold Belfer, MD</last_name>
      <phone>974-54-2405895</phone>
      <email>RahelGB@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rachel Ginold Belfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Malfertheiner P, Megraud F. Management of helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut.61 (5):646-64.2012 Hatcher H , Planalp R . Curcumin: from ancient medicine to cuurent clinical trials. Cell Mol Life Sci. 65(11):1631-52. 2008. Forty-Ludwig A, Neumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori - infected epithelial cells. Biochem Biophys Res Commun. 316(4): 1065-72. 2004</citation>
  </reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>December 13, 2014</last_update_submitted>
  <last_update_submitted_qc>December 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rabin Medical Center</investigator_affiliation>
    <investigator_full_name>Gingold Belfer Rachel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

